4). 1). 5 g Every 8 hours 2 hours Duration of treatment should be in accordance with the site of infection. 5 g Every 8 hours 2 hours Guided by the severity of the infection, the pathogen(s) and the patient’s clinical and bacteriological progress5 1 CrCL estimated using the Cockcroft-Gault formula.
2 To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process. 3 To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
4 The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy. 5 There is very limited experience with the use of Zavicefta for more than 14 days. 1). 5 g Every 8 hours 2 hours cIAI2,3 OR cUTI including pyelonephritis3 OR HAP/VAP3 OR Infections due to aerobic Gram-negative organisms in patients with limited treatment options (LTO)2,3 3 months to < 6 months6 40 mg/kg/10 mg/kg Every 8 hours 2 hours cIAI: 5 – 14 days cUTI4: 5 – 14 days HAP/VAP: 7 – 14 days LTO: Guided by the severity of the infection, the pathogen(s) and the patient’s clinical and bacteriological progress5 1 CrCL estimated using the Schwartz bedside formula.
2 To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process. 3 To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
4 The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy. 5 There is very limited experience with the use of Zavicefta for more than 14 days. 2). 6). 8 Paediatric patients studied from 3 to 12 months of age were full term (≥ 37 weeks gestation).
5 mg/kg 31 to ≤ 44 wee ks PMA7 20 mg/kg/5 mg/kg Every 8 hours 2 hours cIAI1,2 OR cUTI including pyelonephrit is2 OR HAP/VAP2 OR Infections due to aerobic Gram-negati ve organisms in patients with limited treatment options (LTO)1,2 Preterm neonates and infants6 26 to < 31 wee ks PMA7,8 20 mg/kg/5 mg/kg Every 12 hours 2 hours cIAI: 5 – 14 days cUTI3: 5 – 14 days HAP/VA P: 7 – 14 days LTO: Guided by the severity of the infection, the pathogen( s) and the patient’s clinical and bacteriolo gical progress4 1 To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
2 To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. 3 The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy.
4 There is very limited experience with the use of Zavicefta for more than 14 days. 6). 6 Preterm defined as < 37 weeks gestation. 7 Postmenstrual age. 2). 9 Patients with serum creatinine at or below the upper limit of normal for age. 2).
2).
Dosage in adults with CrCL ≤ 50 mL/min Table 4:
Recommended dose for adults with estimated CrCL1 ≤ 50 mL/min Age group Estimated CrCL (mL/min) Dose of ceftazidime/avibactam2,4 Frequency […]